Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pain Manag Nurs ; 20(2): 158-163, 2019 04.
Article in English | MEDLINE | ID: mdl-30442567

ABSTRACT

BACKGROUND: Effective acute pain management following injury is critical to improve short-and long-term patient outcomes. Analgesics can effectively reduce pain intensity, yet half of injury patients report moderate to severe pain during hospitalization. PURPOSE: The primary aim of this study was to identify the analgesic, different analgesic combinations, or analgesic and adjuvant analgesic combination that generated the largest percent change from pre- to post-analgesic pain score. DESIGN: This was a descriptive retrospective cohort study of 129 adults admitted with lower extremity fractures to a trauma center. METHODS: Name, dose, and frequency of analgesics and adjuvant analgesics administered from admission to discharge were collected from medical records. Percent change was calculated from pain scores documented on the 0-10 numeric rating scale. RESULTS: The analgesic with largest percent change from pre- to post-administration pain score was hydromorphone 2 mg IV (53%) for the emergency department and morphine 4 mg IV (54%) for the in-patient unit. All analgesics administered in the emergency department and ∼50% administered on the in-patient unit produced a minimal (15%) decrease in pain score. CONCLUSIONS: This study revealed that few analgesics administered in the emergency department and the in-patient unit to patients with lower extremity fractures provide adequate pain relief. In the emergency department, all analgesics administered resulted in at least minimal improvement of pain. On the in-patient unit 13 analgesic doses resulted at least minimal improvement in pain while nine doses did not even reach 20% change in pain. Findings from this study can be used guide the treatment of fracture pain in the hospital.


Subject(s)
Analgesics/standards , Fractures, Bone/drug therapy , Pain Measurement/statistics & numerical data , Adult , Amitriptyline/analogs & derivatives , Amitriptyline/standards , Amitriptyline/therapeutic use , Analgesics/therapeutic use , Anticonvulsants/standards , Anticonvulsants/therapeutic use , Antidepressive Agents/standards , Antidepressive Agents/therapeutic use , Baclofen/standards , Baclofen/therapeutic use , Bones of Lower Extremity/drug effects , Bones of Lower Extremity/injuries , Cohort Studies , Duloxetine Hydrochloride/standards , Duloxetine Hydrochloride/therapeutic use , Female , Gabapentin/standards , Gabapentin/therapeutic use , Hospitalization/statistics & numerical data , Humans , Male , Middle Aged , Muscle Relaxants, Central/standards , Muscle Relaxants, Central/therapeutic use , Pain Management/methods , Pain Management/standards , Pain Measurement/methods , Pregabalin/standards , Pregabalin/therapeutic use , Retrospective Studies
2.
AAPS PharmSciTech ; 19(7): 2801-2807, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30120695

ABSTRACT

A quantitative, model-based risk assessment process was evaluated using Bayesian parameter estimation to determine the posterior distribution of the probability of a model tablet formulation's (gabapentin) ability to meet end-of-expiry stability criteria-based manufacturing controls. Experimental data was obtained from an FDA-supported, multi-year project that involved researchers at nine universities working collaboratively with industrial and governmental scientists under the leadership of the National Institute for Pharmaceutical Technology and Education (NITPE). The risk assessment process involved the development of a design space manufacturing model and shelf life stability model that shared stability-related critical quality attributes (CQAs). Monte Carlo simulations of the design space and shelf life models that uses model parameter uncertainty to estimate the probability of shelf life failure as a function of manufacturing control. The resultant linked design space and shelf life stability models were tested by comparing model predicted and observed long-term stability data generated under a variety of pilot scale production conditions.


Subject(s)
Gabapentin/standards , Technology, Pharmaceutical/methods , Technology, Pharmaceutical/standards , United States Food and Drug Administration/standards , Analgesics/chemistry , Analgesics/standards , Bayes Theorem , Drug Stability , Gabapentin/chemistry , Risk Assessment , Tablets , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...